Evidence map›Paper›PMID 36312002›Full record

Trial reportWorld journal of diabetes2022

Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus.

Xiao-Fen Lian, Dong-Hui Lu, Hong-Li Liu, Yan-Jing Liu, Xiu-Qun Han, Yang Yang, Yuan Lin, Qing-Xiang Zeng, Zheng-Jie Huang, Feng Xie and 5 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiao-Fen LianDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Dong-Hui LuDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Hong-Li LiuDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Yan-Jing LiuDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Xiu-Qun HanDepartment of Research & Development, Zhejiang MaiDa Gene Tech Co. Ltd, Zhoushan 316000, Zhejiang Province, China.
Yang YangDepartment of Endocrinology, Huizhou Central People's Hospital, Huizhou 516000, Guangdong Province, China.
Yuan LinDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Qing-Xiang ZengDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Zheng-Jie HuangDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Feng XieDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Cai-Hao HuangDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China.
Hong-Mei WuDepartment of Endocrinology, Longgang District Central Hospital of Shenzhen, Shenzhen 518000, Guangdong Province, China.
Ai-Mei LongDepartment of Endocrinology, Longgang District Central Hospital of Shenzhen, Shenzhen 518000, Guangdong Province, China.
Ling-Ping DengDepartment of Endocrinology, Longgang District Central Hospital of Shenzhen, Shenzhen 518000, Guangdong Province, China.
Fan ZhangDepartment of Endocrinology, Peking University Shenzhen Hospital, Shenzhen 518000, Guangdong Province, China. bjdxszyynfm@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgressive pancreatic β-cell dysfunction is a fundamental part of the pathology of type 2 diabetes mellitus (T2DM). Cellular therapies offer novel opportunities for the treatment of T2DM to improve the function of islet β-cells.

aimTo evaluate the effectiveness and safety of human umbilical cord-mesenchymal stem cell (hUC-MSC) infusion in T2DM treatment.

methodsSixteen patients were enrolled and received 1 × 10

resultsDuring the entire intervention period, the fasting plasma glucose level was significantly reduced [baseline: 9.3400 (8.3575, 11.7725), day 14 ± 3: 6.5200 (5.2200, 8.6900);

conclusionThe results of this study suggest that hUC-MSC infusion can improve glycemia, restore islet β-cell function, and reduce the dosage of hypoglycemic agents without serious AEs. Thus, hUC-MSC infusion may be a novel option for the treatment of T2DM.

Indexed as

Blood glucoseHomeostasis model assessment of β-cell functionHuman umbilical cord mesenchymal stem cellsHypoglycemic agentsType 2 diabetes

Identifiers

PMID36312002
PMCPMC9606793

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.